Market Exclusive

Analyst Upgrades – VRX – Valeant Pharmaceuticals International (NYSE:VRX) Stock Gets Upgraded By Mizuho from Underperform to Neutral

Analyst Ratings For VRX – Valeant Pharmaceuticals International (NYSE:VRX)

Today, VRX – Valeant Pharmaceuticals International (NYSE:VRX) stock received an upgrade by Mizuho from Underperform to Neutral with a price target of $15.00.

Some recent analyst ratings include

Recent Insider Trading Activity For VRX – Valeant Pharmaceuticals International (NYSE:VRX)
VRX – Valeant Pharmaceuticals International (NYSE:VRX) has insider ownership of 5.87% and institutional ownership of 50.10%.

Recent Trading Activity for VRX – Valeant Pharmaceuticals International (NYSE:VRX)
Shares of VRX – Valeant Pharmaceuticals International closed the previous trading session at 15.74 down -0.05 0.32% with 15.699999809265137 shares trading hands.

Exit mobile version